Jeremy Bender, Day One Biopharmaceuticals CEO

Day One en­ters ADC field, go­ing af­ter a tar­get that once at­tract­ed Ab­b­Vie and now Gen­mab

Short­ly af­ter se­cur­ing its first FDA ap­proval and bag­ging $108 mil­lion from a pri­or­i­ty re­view vouch­er sale, Day One …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.